Total Payments
$1.4M
2024 Payments
$220,186
Companies
38
Transactions
1,183
Medicare Patients
481
Medicare Billing
$107,603
Payment Breakdown by Category
Other$895,045 (64.6%)
Consulting$321,749 (23.2%)
Travel$122,811 (8.9%)
Food & Beverage$28,162 (2.0%)
Research$17,469 (1.3%)
Education$282.69 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $894,445 | 314 | 64.6% |
| Consulting Fee | $321,749 | 93 | 23.2% |
| Travel and Lodging | $122,811 | 315 | 8.9% |
| Food and Beverage | $28,162 | 443 | 2.0% |
| Unspecified | $17,469 | 12 | 1.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $600.00 | 1 | 0.0% |
| Education | $282.69 | 5 | 0.0% |
Payments by Type
General
$1.4M
1,171 transactions
Research
$17,469
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $413,722 | 387 | $0 (2024) |
| GlaxoSmithKline, LLC. | $284,118 | 222 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $252,794 | 210 | $0 (2024) |
| GENZYME CORPORATION | $245,080 | 144 | $0 (2024) |
| Insmed, Inc. | $31,878 | 25 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $31,552 | 34 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $29,000 | 10 | $0 (2022) |
| Amgen Inc. | $27,214 | 30 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20,679 | 20 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $19,368 | 14 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $220,186 | 171 | AstraZeneca Pharmaceuticals LP ($97,109) |
| 2023 | $199,476 | 197 | AstraZeneca Pharmaceuticals LP ($99,626) |
| 2022 | $244,638 | 167 | AstraZeneca Pharmaceuticals LP ($89,702) |
| 2021 | $221,762 | 152 | AstraZeneca Pharmaceuticals LP ($68,276) |
| 2020 | $91,269 | 54 | GlaxoSmithKline, LLC. ($36,397) |
| 2019 | $289,676 | 265 | GlaxoSmithKline, LLC. ($98,660) |
| 2018 | $87,403 | 115 | Regeneron Healthcare Solutions, Inc. ($21,310) |
| 2017 | $31,108 | 62 | GlaxoSmithKline, LLC. ($15,016) |
All Payment Transactions
1,183 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $683.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $150.93 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $115.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | Cash or cash equivalent | $3,550.00 | General |
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | In-kind items and services | $1,184.15 | General |
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | In-kind items and services | $1,037.44 | General |
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | In-kind items and services | $31.89 | General |
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Electromed, Inc. | SMARTVEST (Device) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: HFCWO | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,973.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,973.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $491.96 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $85.68 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,973.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/05/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $805.50 | General |
| Category: Respiratory | ||||||
| 10/30/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,762.00 | General |
| Category: Immunology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $122.13 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,762.00 | General |
| Category: Immunology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,079 | 3 |
| A phase 3, 7 month, randomized, double blind parallel group, placebo controlled, multi-center trial with a 5 month extension period to assess the efficacy, safety, tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAB-E25 in adoloescents and adults requiring daily treatment with inhaled corticosteroids US, A phase 3, 7 month, randomized, double blind parallel group, placebo controlled, multi-center trial with a 5 month extension period to assess the | F. Hoffmann-La Roche AG | $4,199 | 2 |
| IMPROVED ACTIVITY LEVELS IN PATIENTS WITH ASTHMA A POST HOC ANALYSIS OF OMALIZUMAB THERAPY | F. Hoffmann-La Roche AG | $3,941 | 3 |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study | GENZYME CORPORATION | $1,000 | 3 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | GENZYME CORPORATION | $250.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 96 | 203 | $77,992 | $24,296 |
| 2022 | 2 | 103 | 244 | $108,125 | $33,901 |
| 2021 | 6 | 132 | 220 | $72,350 | $23,256 |
| 2020 | 6 | 150 | 245 | $83,418 | $26,150 |
Total Patients
481
Total Services
912
Medicare Billing
$107,603
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 28 | 97 | $50,824 | $16,082 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 81 | $20,631 | $5,883 | 28.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 25 | $6,537 | $2,332 | 35.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 47 | 165 | $87,780 | $27,879 | 31.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 56 | 79 | $20,345 | $6,022 | 29.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 42 | 114 | $60,978 | $19,618 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 40 | $9,480 | $3,126 | 33.0% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 16 | 16 | $576.00 | $154.56 | 26.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 20 | 22 | $528.00 | $144.54 | 27.4% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 16 | 16 | $416.00 | $114.24 | 27.5% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 12 | 12 | $372.00 | $99.12 | 26.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 43 | 129 | $70,563 | $23,023 | 32.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 29 | $5,655 | $1,501 | 26.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 19 | 20 | $5,275 | $1,151 | 21.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2020 | 30 | 32 | $800.00 | $201.30 | 25.2% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2020 | 18 | 18 | $666.00 | $157.76 | 23.7% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 17 | 17 | $459.00 | $116.77 | 25.4% |
About Dr. Diego Maselli Caceres, M.D
Dr. Diego Maselli Caceres, M.D is a Pulmonary Disease healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2009. The National Provider Identifier (NPI) number assigned to this provider is 1609000421.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Diego Maselli Caceres, M.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $220,186 received in 2024. These payments were reported across 1,183 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($894,445).
As a Medicare-enrolled provider, Maselli Caceres has provided services to 481 Medicare beneficiaries, totaling 912 services with total Medicare billing of $107,603. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location San Antonio, TX
- Active Since 05/07/2009
- Last Updated 07/26/2012
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1609000421
Products in Payments
- DUPIXENT (Biological) $418,214
- NUCALA (Biological) $143,713
- TEZSPIRE (Biological) $141,178
- FASENRA (Biological) $87,677
- BREZTRI (Drug) $69,224
- FASENRA (Drug) $47,757
- TRELEGY ELLIPTA (Drug) $46,565
- DUPIXENT (Drug) $36,339
- AIRSUPRA (Drug) $35,852
- LONHALA MAGNAIR (Drug) $31,552
- DUPIXENT DUPILUMAB INJECTION (Biological) $29,188
- XOLAIR (Biological) $14,412
- STIOLTO RESPIMAT (Drug) $13,425
- NO PRODUCT DISCUSSED (Drug) $12,362
- Xolair (Biological) $9,925
- ANORO (Drug) $8,495
- BREZTRI AEROSPHERE (Drug) $3,025
- Yupelri (Drug) $2,394
- AREXVY (Drug) $1,357
- SMARTVEST (Device) $1,310
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in San Antonio
Antonio Anzueto, Md, MD
Pulmonary Disease — Payments: $2.0M
Pulmonary Disease $2.0M
Dr. David Marks, M.d, M.D
Pulmonary Disease — Payments: $380,161
Pulmonary Disease $380,161
Charles Andrews, M.d, M.D
Pulmonary Disease — Payments: $295,102
Pulmonary Disease $295,102
Napoleon Puente Cuellar, M.d, M.D
Pulmonary Disease — Payments: $185,010
Pulmonary Disease $185,010
Dr. Anoop Nambiar, M.d, M.D
Pulmonary Disease — Payments: $152,462
Pulmonary Disease $152,462
Soma Jyothula, Md, MD
Pulmonary Disease — Payments: $133,953
Pulmonary Disease $133,953